Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months

Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms

Granules India posts Q4 FY24 consolidated PAT at Rs. 129.64 Cr

The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024

Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr

The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024

Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer

225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer

IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr

The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024

Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr

The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr

The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024